Previously Treated Cancer and Recurrence

Chapter 13: Previously Treated Prostate Cancer — Detecting and Managing Recurrence

Opening Story: David's Journey

David, a 62-year-old engineer, had surgery for his intermediate-risk prostate cancer three years ago. His PSA had been undetectable — until his latest blood test showed 0.15 ng/mL. Three months later, it was 0.22 ng/mL. His heart sank. "Does this mean my cancer is back? Did the surgery fail?"

His urologist reassured him: "A rising PSA does not mean the end of the road. It means we need to investigate, and if treatment is needed, we have excellent options — especially when we catch it early like this."

David underwent a PSMA PET scan, which showed a small area of uptake in the prostate bed — no spread anywhere else. He received a course of salvage radiation therapy, and within months his PSA was undetectable again. Five years later, it remains undetectable.

David's story is common. Recurrence is not a death sentence — it is a manageable chapter in the prostate cancer journey.

Part 1: Understanding Recurrence — The Big Picture

If your PSA starts rising after treatment, it is natural to feel scared. But here is the most important thing to understand: a rising PSA does not mean your first treatment failed, and it does not mean you are going to die from prostate cancer.

Biochemical recurrence — meaning a rise in PSA as the only sign of possible cancer return — occurs in about 20–40% of men who undergo surgery or radiation.¹ ² That sounds like a lot, but here is the reassuring part: even without any additional treatment, 10-year metastasis-free survival rates are up to 86%, and prostate cancer-specific mortality is only about 5%.³ ⁴ Most men with a rising PSA will never develop symptoms from their cancer.

Types of Recurrence

Not all recurrences are the same. Understanding the type helps determine the best approach:

• Biochemical recurrence (BCR): PSA is rising, but there is no cancer visible on any imaging study. This is the earliest and most common form of recurrence.
• Local recurrence: Cancer has returned in the area where the prostate was (the "prostate bed" after surgery) or within the prostate itself (after radiation). This is often curable with additional local treatment.
• Regional recurrence: Cancer has spread to nearby lymph nodes in the pelvis. This can often be treated effectively with radiation and/or hormone therapy.
• Distant recurrence (metastatic): Cancer has spread to bones, distant lymph nodes, or organs. This requires systemic (whole-body) treatment but is still very manageable with modern therapies.

The Most Important Message: You Have Time

Prostate cancer recurrence is almost never an emergency. You have weeks to months to get the right tests, see the right doctors, and make a thoughtful decision. Do not rush.

Part 2: Recurrence After Surgery (Radical Prostatectomy)

2A: What Should PSA Do After Surgery?

After radical prostatectomy, the entire prostate gland has been removed. Since PSA is produced almost exclusively by prostate cells, your PSA should drop to undetectable levels (essentially zero) within about 6 weeks after surgery.⁵ ⁶

Your doctor will check PSA at approximately 6 weeks after surgery, then every 6–12 months for the first 5 years, and annually thereafter.⁷ The AUA/ASTRO guideline recommends PSA every 3–6 months for the first 2 years, then every 6 months through year 5, then annually.⁸

2B: PSA Persistence vs. PSA Recurrence

There are two patterns of PSA rise after surgery, and they have different implications:

• PSA persistence: PSA never drops to undetectable levels after surgery. This may mean that some cancer cells were left behind — either in the surgical area or elsewhere in the body.
• PSA recurrence: PSA initially becomes undetectable (good news — the surgery worked locally), but then starts rising again months or years later. This means cancer cells that were too small to detect at the time of surgery have grown enough to produce measurable PSA.

2C: How Is Biochemical Recurrence Defined After Surgery?

Different organizations use slightly different definitions:

• NCCN definition: PSA does not fall to undetectable levels (persistence), OR undetectable PSA with a subsequent detectable PSA that increases on 2 or more determinations, OR PSA rises above 0.1 ng/mL.⁹
• AUA definition: PSA ≥0.2 ng/mL with a confirmatory value >0.2 ng/mL.⁸

The exact number matters less than the trend. A consistently rising PSA is what triggers further evaluation.

2D: Understanding Your Post-Surgery Pathology Report

After surgery, the pathologist examines the entire prostate under the microscope. This final pathology report contains critical information that helps predict your risk of recurrence:

• Surgical margins: Did the surgeon remove all the cancer? A "positive margin" means cancer cells were found at the very edge of the removed tissue, suggesting some cancer may have been left behind. A "negative margin" means a rim of normal tissue surrounded the cancer — a good sign.
• Extracapsular extension (ECE): Did the cancer grow through the outer shell (capsule) of the prostate? If yes, this is called pT3a disease and increases recurrence risk.
• Seminal vesicle invasion (SVI): Did the cancer invade the seminal vesicles (small glands attached to the prostate)? If yes, this is pT3b disease — a higher risk finding.
• Lymph node status: Were any lymph nodes positive for cancer? If yes (pN1), this indicates the cancer had begun to spread regionally.
• Gleason score / Grade Group on final pathology: Sometimes the grade is higher on the surgical specimen than on the original biopsy. This is called "upgrading" and may change your risk category.
• Percentage of the prostate involved: How much of the gland contained cancer.

2E: Genomic Classifiers After Surgery

In addition to the traditional pathology report, your doctor may order a genomic test on the surgical tissue. These tests analyze the genes within your cancer to predict how aggressively it may behave:

• Decipher: The most widely studied genomic classifier in the post-surgery setting. It provides a score from 0 to 1, with higher scores indicating higher risk of metastasis. Decipher can help decide whether you need additional treatment (like radiation) after surgery, and how urgently.¹⁰
• Prolaris and Oncotype DX: Also provide prognostic information, though they are used less commonly in the post-surgical setting than Decipher.

These tests are particularly helpful when the pathology report shows borderline findings — for example, a positive margin but otherwise favorable features. The genomic score can tip the balance toward treatment or monitoring.

2F: Risk Stratification After Surgery — Who Is at Higher Risk?

Several factors predict a higher risk of recurrence after surgery:

• PSA persistence (never became undetectable)
• Short PSA doubling time (PSADT) — how fast the PSA is rising. A PSADT less than 9–12 months is concerning; less than 6 months is high risk.¹¹
• High Gleason score / Grade Group (especially Grade Group 4–5) on final pathology
• Positive surgical margins
• Extracapsular extension or seminal vesicle invasion (pT3)
• Positive lymph nodes (pN1)
• Early recurrence (within 1–2 years of surgery)
• High Decipher score

Part 3: Treatment Options for Recurrence After Surgery

3A: The Great Debate — Adjuvant vs. Early Salvage Radiation

For decades, doctors debated whether men with high-risk features after surgery should receive radiation immediately (adjuvant radiation) or wait and only treat if PSA starts rising (early salvage radiation).

This question has now been answered by three landmark randomized trials — RADICALS-RT, RAVES, and GETUG-AFU 17 — and their combined analysis called the ARTISTIC meta-analysis.¹² ¹³ ¹⁴ ¹⁵

The verdict: Early salvage radiation is now the preferred approach for most patients. The ARTISTIC meta-analysis of 2,053 patients showed no difference in event-free survival between adjuvant and early salvage radiation (HR 0.95; 95% CI 0.75–1.21).¹⁵ Importantly, adjuvant radiation caused more urinary and bowel side effects.¹²

This means that instead of giving radiation to every man with high-risk features (many of whom would never recur), doctors now monitor PSA and only treat those whose PSA actually rises. This approach spares about 60% of men from unnecessary radiation and its side effects.¹²

Important exception: For men with multiple adverse features (such as pT3b with positive margins AND positive lymph nodes), adjuvant radiation may still be reasonable. These high-risk patients were underrepresented in the trials, and the RADICALS-RT trial showed a significant reduction in prostate cancer-specific mortality with adjuvant radiation in this subgroup.¹⁶

3B: Salvage Radiation Therapy — The Main Treatment

Salvage radiation therapy (also called "secondary radiation therapy" — the NCCN prefers this term to avoid the negative connotation of "salvage") is the primary treatment for PSA recurrence after surgery when there is no evidence of distant spread.⁹ ¹⁷

How it works: Radiation is directed at the prostate bed (the area where the prostate used to be) to destroy any remaining cancer cells. Sometimes the pelvic lymph nodes are also treated.

When to start — earlier is better: This is one of the most important messages in this chapter. Multiple studies involving over 6,000 patients show that salvage radiation works best when given at lower PSA levels.⁸ ¹⁸

• The AUA/ASTRO/SUO guideline recommends providing salvage radiation when PSA is ≤0.5 ng/mL.⁸
• For high-risk patients, salvage radiation may be offered even when PSA is below 0.2 ng/mL.⁸
• One study showed 10-year overall survival of 84% for men treated at PSA 0.01–0.2 ng/mL vs. 61% for those treated at PSA >0.5 ng/mL.¹⁸

Bottom line: Do not wait for PSA to climb high. The lower the PSA at the time of salvage radiation, the better the outcome.

Even with negative PSMA PET imaging, salvage radiation is still recommended at PSA 0.5 ng/mL because outcomes are superior when treatment is delivered below this threshold.³ ⁴

Dose and fractionation: Salvage radiation is typically delivered as:

• Conventionally fractionated: 64–70.2 Gy in 32–39 treatments
• Moderately hypofractionated: 52.5 Gy in 20 treatments or 62.5 Gy in 25 treatments (shown to be equally effective with similar side effects)
• Ultra-hypofractionated (investigational): 32.5–34 Gy in 5 treatments — early results are promising but this approach is still being studied.¹⁶

3C: Adding Hormone Therapy to Salvage Radiation

Should hormone therapy (ADT) be added to salvage radiation? This depends on your risk factors. Three major trials have addressed this question:

• GETUG-AFU 16: 743 men with BCR after surgery. Adding 6 months of ADT to salvage radiation improved 10-year progression-free survival (64% vs. 49%) and metastasis-free survival (75% vs. 69%), but did not improve overall survival.¹⁹
• RTOG 9601: 760 men with BCR. Adding 24 months of bicalutamide (an anti-androgen) to salvage radiation improved overall survival at 13 years, but the benefit was primarily in men with higher PSA levels (>0.7 ng/mL).²⁰
• SPPORT (NRG/RTOG 0534): 1,792 men randomized to three arms. Adding short-term ADT (4–6 months) plus pelvic lymph node radiation to prostate bed radiation improved freedom from progression.²¹

Current recommendations:

• The NCCN recommends salvage EBRT ± ADT for men with PSA recurrence and no evidence of metastatic disease.⁹
• The AUA/ASTRO/SUO guideline recommends offering ADT with salvage radiation for patients with any high-risk features (PSA ≥0.7 ng/mL, Grade Group 4–5, PSADT ≤6 months, persistent PSA, seminal vesicle invasion).⁸
• For patients receiving early salvage radiation at low PSA levels, there is no clear overall survival benefit from adding ADT. ADT does delay biochemical recurrence but adds side effects.¹⁶
• Generally, short-term ADT (4–6 months) is recommended to balance efficacy and quality of life. Longer-term ADT (18–24 months) may be preferred for men with multiple adverse features or late salvage radiation.¹⁹ ²²
• Adding pelvic lymph node radiation to salvage radiation plus ADT improves biochemical control, especially in men with higher PSA levels or those who did not have a thorough lymph node dissection at surgery.²¹ ²³

3D: The Role of PSMA PET in Guiding Salvage Treatment

PSMA PET-CT has revolutionized how we detect and manage recurrent prostate cancer. This advanced imaging test can find cancer at much lower PSA levels than traditional CT or bone scans.

Detection rates by PSA level:

• PSA 0.5 ng/mL: approximately 36–57% detection rate²⁴ ²⁵ ²⁶
• PSA 0.5–1.0 ng/mL: approximately 45–60%²⁴ ²⁵
• PSA 1.0–2.0 ng/mL: approximately 57–84%²⁴
• PSA ≥2.0 ng/mL: approximately 77–91%²⁴ ²⁵

A 2025 systematic review and meta-analysis of 43 studies (8,119 patients) confirmed that PSMA PET positivity increases with PSA level, from 48% at PSA 0.2–0.5 ng/mL to over 90% at PSA >2 ng/mL.²⁷

How PSMA PET changes treatment:

• It can identify whether recurrence is local (prostate bed), regional (pelvic lymph nodes), or distant (bones, distant nodes) — which directly affects treatment planning.²⁸
• In one study, therapeutic strategies were modified in 84% of PET-positive cases.²⁸
• However, a negative PSMA PET does NOT mean there is no cancer. At low PSA levels, the cancer may simply be too small to detect. Salvage radiation should still be offered based on PSA kinetics, even with a negative scan.³ ⁴ ⁹

3E: What If PSA Rises Again After Salvage Radiation? (Second Recurrence)

If PSA rises again after salvage radiation (a "second biochemical recurrence"), the approach depends on risk stratification:⁹ ²⁹

For low-risk second BCR (slow PSA doubling time, favorable features):

• Monitoring (preferred) — with PSA every 3–6 months and imaging for symptoms or rising PSA
• ADT if monitoring is not preferred

For high-risk second BCR (PSADT ≤9 months and other adverse features):

• Enzalutamide ± leuprolide — based on the landmark EMBARK trial
• Apalutamide + ADT (category 2B)
• ADT alone
• Monitoring

The EMBARK Trial — A Game-Changer for High-Risk BCR

The EMBARK trial is one of the most important recent advances for men with high-risk biochemical recurrence. This phase 3 trial randomized 1,068 men with high-risk BCR (PSADT ≤9 months, no metastases on conventional imaging) to three groups: enzalutamide + leuprolide, leuprolide alone, or enzalutamide monotherapy.³⁰ ³¹

Key results:

• Metastasis-free survival: Enzalutamide + leuprolide reduced the risk of metastasis by 58% compared to leuprolide alone (HR 0.42).³⁰
• Overall survival: The final analysis showed 8-year overall survival of 78.9% with enzalutamide + leuprolide vs. 69.5% with leuprolide alone — a 40% reduction in the risk of death (HR 0.60; P0.001).³¹
• Enzalutamide monotherapy improved metastasis-free survival but did NOT significantly improve overall survival compared to leuprolide alone (HR 0.83; P=0.19). However, it better preserved sexual function and remains an option for men who prioritize sexual health.³¹ ³²
• Treatment suspension: An innovative feature of EMBARK was that treatment was suspended if PSA became undetectable at week 36, and only restarted if PSA rose again. This intermittent approach reduced side effect burden.³³

Based on EMBARK, enzalutamide became the first and only androgen receptor pathway inhibitor (ARPI) approved for high-risk biochemical recurrence.³³

Part 4: Recurrence After Radiation Therapy

4A: What Should PSA Do After Radiation?

Unlike after surgery, the prostate is still in your body after radiation. PSA does NOT drop to zero. Instead, it declines slowly over months to years. The lowest point is called the "nadir," and it may take 2–5 years to reach.³

4B: PSA Bounce vs. True Recurrence

This is one of the most anxiety-provoking aspects of follow-up after radiation. A PSA bounce is a temporary rise in PSA that is NOT cancer recurrence. It occurs in about 25–30% of men, particularly younger men and those treated with brachytherapy. The bounce typically happens 12–24 months after treatment and resolves on its own.

How to tell the difference:

• A PSA bounce is usually small (less than 0.5 ng/mL above nadir), temporary, and resolves within months.
• True recurrence shows a persistent, progressive rise in PSA.
• Your doctor will monitor the trend over several months before concluding that recurrence has occurred.

4C: How Is Biochemical Recurrence Defined After Radiation?

The standard definition is the Phoenix definition: PSA nadir + 2.0 ng/mL.³⁴ ³⁵

For example, if your lowest PSA after radiation was 0.5 ng/mL, biochemical recurrence would be defined as PSA rising to 2.5 ng/mL.

Important nuance: The NCCN notes that a recurrence evaluation should be considered when PSA is confirmed to be increasing even if the rise above nadir is less than 2 ng/mL, especially in younger, healthier patients who are candidates for additional local treatment.³⁵ A rapid PSA rise may warrant prostate biopsy before meeting the Phoenix definition.

4D: Impact of Prior Radiation Type

The type of radiation you received affects both recurrence patterns and salvage options:

• After EBRT alone: The full range of salvage options is available.
• After brachytherapy: Seeds remain in the prostate, which can complicate some salvage procedures (especially additional brachytherapy or surgery). HIFU and cryotherapy may be preferred in some cases.
• After combination therapy (EBRT + brachytherapy): The prostate has received the highest total radiation dose, which may limit reirradiation options and increase the risk of side effects from any salvage procedure.

4E: Confirming Local Recurrence

Before pursuing local salvage treatment, it is important to confirm that the recurrence is actually in the prostate (and not elsewhere):

• MRI: Can identify suspicious areas within the prostate.
• PSMA PET-CT: Can detect both local and distant recurrence. In the post-radiation setting, PSMA PET positivity rates are higher than post-surgery (92% overall), likely because PSA levels are typically higher at the time of evaluation.²⁷
• Prostate biopsy: Required to confirm local recurrence before any local salvage therapy. The biopsy should target suspicious areas identified on MRI or PET.

4F: Distinguishing Local from Distant Recurrence

This distinction is critical because it determines treatment:

• Local-only recurrence: Potentially curable with local salvage therapy.
• Regional recurrence (pelvic nodes): May benefit from radiation ± hormone therapy, or metastasis-directed therapy.
• Distant recurrence: Requires systemic therapy (see Part 7).

PSMA PET-CT is the best tool for making this distinction.²⁷

Part 5: Treatment Options for Recurrence After Radiation

Treating recurrence after radiation is more complex than treating recurrence after surgery. The prostate and surrounding tissues have already been irradiated, which increases the risk of side effects from any additional local treatment. However, multiple effective options exist.

5A: Local Salvage Options

The NCCN lists the following local therapy options for biopsy-proven recurrence in the prostate after prior radiation, without distant metastatic disease:³⁶

• Cryotherapy — freezing the prostate tissue
• High-intensity focused ultrasound (HIFU) — using focused sound waves to heat and destroy cancer
• Irreversible electroporation (IRE) — using electrical pulses to destroy cancer cells (category 2B — less evidence)
• Reirradiation — LDR brachytherapy, HDR brachytherapy, or SBRT
• Salvage radical prostatectomy (RP) + pelvic lymph node dissection

How do these options compare?

The MASTER meta-analysis (150 studies) found that adjusted 5-year recurrence-free survival ranged from 50% (cryotherapy) to 60% (HDR brachytherapy and SBRT), with no significant differences between any modality and salvage RP.³⁷ However, reirradiation (SBRT, HDR, LDR brachytherapy) was associated with significantly less severe urinary toxicity than salvage RP (5.6–9.6% vs. 20%).³⁷

A 2026 matched cohort study of 923 patients comparing salvage focal therapy (HIFU or cryotherapy) vs. salvage RP found no significant difference in 10-year cancer-specific survival (92% vs. 99%; P=0.15) or overall survival. However, salvage RP was associated with approximately 24 times higher odds of any complication and 9 times higher odds of major complications.³⁸

A 2026 systematic review and meta-analysis confirmed that local salvage therapies alone (without ADT) can effectively delay the need for hormone therapy, with more than half of patients remaining ADT-free at 5 years across all modalities.³⁹

Key points about each option:

• Salvage RP: Most invasive but provides a complete pathology specimen. High rates of incontinence (~60% requiring daily pads) and erectile dysfunction (~85%). Should be performed at experienced centers.³⁸ ⁴⁰
• Salvage HIFU: Less invasive, can be focal (treating only the area of recurrence). Lower incontinence rates than RP. Preferred for posterior tumors.³⁸ ⁴⁰
• Salvage cryotherapy: Can treat anterior tumors and larger volumes. Similar efficacy to HIFU. Risk of urethral sloughing and fistula.³⁷
• Salvage reirradiation (HDR brachytherapy, LDR brachytherapy, SBRT): Supported by phase II trials with >36 months follow-up. Should be strongly considered in patients with >2 years since prior radiation who do not have ongoing moderate or higher grade radiation toxicities. Lower severe GU toxicity than RP.³⁶ ³⁷ ⁴¹

5B: Hormone Therapy for Recurrence After Radiation

When local salvage is not feasible or not desired, hormone therapy (ADT) is an option. The timing of ADT initiation should consider PSA doubling time and Grade Group.³⁵ ADT should not be reflexively ordered — monitoring is also an option, especially for men with slow PSA doubling times.³⁶

5C: The Importance of Experienced Centers

The NCCN recommends that patients receiving local salvage therapy for radiation recurrence be treated within clinical trials when available and/or at experienced centers.³⁶ These are complex procedures with higher complication rates than primary treatment, and outcomes are better at high-volume centers.

5D: What If PSA Rises After Salvage Local Therapy?

If PSA rises again after salvage local therapy, the approach follows the same principles as second BCR (see Part 3E above): risk stratification, imaging, and consideration of systemic therapy including enzalutamide ± leuprolide for high-risk BCR.²⁹

Part 6: Recurrence in Lymph Nodes Only (Oligorecurrent Nodal Disease)

With the advent of PSMA PET, doctors are increasingly finding recurrences limited to a small number of lymph nodes — a condition called "oligorecurrent" disease.

Treatment options include:

• Metastasis-directed therapy (MDT): SBRT (stereotactic radiation) targeted to the involved lymph nodes. The STOMP, ORIOLE, and WOLVERINE trials (discussed in Chapter 12) showed that MDT can delay progression and potentially improve survival.
• Salvage lymph node dissection: Surgical removal of the involved nodes. This is an option at experienced centers.
• Systemic therapy ± radiation: Hormone therapy with or without radiation to the involved nodes.

The goal of treating oligorecurrent disease is to delay or avoid the need for long-term systemic therapy and its associated side effects.

Part 7: Recurrence as Distant Metastatic Disease

When recurrence is found in bones, distant lymph nodes, or organs, the disease is classified as metastatic castration-sensitive prostate cancer (mCSPC). Treatment follows the same principles outlined in Chapter 12 (Part 8):

• ADT + ARPI (doublet therapy) is the minimum standard
• ADT + ARPI + docetaxel (triplet therapy) for high-volume disease
• Metastasis-directed therapy for oligometastatic recurrence (1–5 metastases)

The key distinction is whether the recurrence is oligometastatic (few metastases, potentially treatable with targeted therapy) or polymetastatic (widespread, requiring systemic therapy).⁹

Part 8: Castration-Resistant Prostate Cancer (CRPC) — When Hormones Stop Working

8A: What Is Castration Resistance?

Castration-resistant prostate cancer (CRPC) means the cancer is growing despite testosterone being at castrate levels (below 50 ng/dL). This does NOT mean the cancer is untreatable — it means the cancer has found ways to grow even without normal testosterone levels.⁴²

CRPC is defined as cancer that progresses clinically, radiographically, or biochemically despite castrate levels of serum testosterone.⁴²

8B: Non-Metastatic CRPC (nmCRPC)

This means PSA is rising despite castrate testosterone, but no metastases are visible on imaging.

PSA doubling time is the key factor:

• PSADT >10 months: Monitoring is preferred, or other secondary hormone therapy.⁴²
• PSADT ≤10 months: Treatment with an ARPI is recommended. Three drugs have shown significant benefit in large randomized trials:⁴²
• Apalutamide (SPARTAN trial) — category 1
• Darolutamide (ARAMIS trial) — category 1
• Enzalutamide (PROSPER trial) — category 1

All three drugs significantly delayed the development of metastases and improved metastasis-free survival. ADT is continued alongside these medications.

8C: Metastatic CRPC (mCRPC)

When cancer has spread and is resistant to initial hormone therapy, multiple treatment options exist. The choice depends on what treatments you have already received, your genetic profile, and your overall health. Treatment options include (discussed in detail in Chapter 10):

• ARPIs (abiraterone, enzalutamide) — if not used previously
• Chemotherapy (docetaxel, cabazitaxel)
• Radiopharmaceuticals (Radium-223 for bone metastases, Lutetium-177 PSMA for PSMA-positive disease)
• Immunotherapy (sipuleucel-T; pembrolizumab for MSI-H/dMMR tumors)
• PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) for men with HRR gene mutations (BRCA1/2, ATM, etc.)

8D: The Importance of Genomic/Molecular Testing

At the CRPC stage, genomic testing becomes especially important because it can identify targetable mutations:

• HRR mutations (BRCA1/2, ATM, PALB2, etc.): Present in approximately 20–25% of mCRPC patients. These men may benefit from PARP inhibitors.
• MSI-H / dMMR: Present in approximately 3–5% of mCRPC patients. These men may respond to immunotherapy (pembrolizumab).
• PSMA expression: Determines eligibility for Lutetium-177 PSMA therapy.

If you have not had genomic testing, ask your doctor about it — especially at the CRPC stage.

Part 9: PSA Kinetics — Understanding How Fast Your Cancer Is Growing

PSA Doubling Time (PSADT) is arguably the single most important number in recurrent prostate cancer. It tells you how fast the cancer is growing by measuring how long it takes for PSA to double.

• PSADT >12 months: Slow-growing. Lower risk. Monitoring may be appropriate.
• PSADT 9–12 months: Intermediate. Closer monitoring and consideration of treatment.
• PSADT 9 months: Fast-growing. Higher risk. Treatment is generally recommended.¹¹ ²⁹
• PSADT 3 months: Very aggressive. Urgent treatment needed.

A population-based study found that among patients who died within 15 years of BCR after surgery with a PSADT 9 months, prostate cancer accounted for ≥92% of those deaths.³³ This underscores why PSADT is used to define "high-risk" BCR.

PSA velocity (how much PSA rises per year) is a related concept but PSADT is more commonly used in the recurrence setting.

Nomograms and calculators can help estimate your individual risk:

• MSKCC nomograms: Available online, these tools combine multiple factors (PSA, Gleason score, stage, time to recurrence) to estimate your probability of remaining cancer-free after salvage treatment.
• CAPRA-S score: A post-surgical risk score that predicts recurrence based on pathologic features.

Part 10: Treatment Sequencing — There Is a Plan

One of the most important concepts in managing recurrent prostate cancer is treatment sequencing — the idea that treatments are given in a logical order, and that "saving" certain therapies for later is part of the strategy.

Think of it like a chess game: your doctor is not just thinking about the next move, but several moves ahead.

General sequence for recurrent prostate cancer:

1. Local salvage therapy (radiation after surgery, or local salvage after radiation) — the first line of defense for local recurrence
2. Hormone therapy (ADT ± ARPI) — when local therapy is not sufficient or not feasible
3. Chemotherapy — when hormone therapy stops working
4. Targeted therapies (PARP inhibitors, immunotherapy) — based on genomic testing
5. Radiopharmaceuticals (Radium-223, Lutetium-177 PSMA) — for specific situations in mCRPC
6. Clinical trials — can be considered at any point, but are especially important when standard options have been exhausted

Not every patient will need every step. Many men are cured with local salvage therapy alone and never need systemic treatment. Others may live for years on hormone therapy with excellent quality of life. The point is: there is always a next step.

Important principles of sequencing:

• Do not use your strongest weapons first if you do not need to. For example, if you have a slow-rising PSA after surgery, salvage radiation alone may be all you need. Adding hormone therapy or chemotherapy at this point would be premature.
• Avoid repeating the same class of drug. If your cancer progressed on one ARPI (for example, abiraterone), switching to another ARPI (enzalutamide) is generally less effective than switching to a different class (chemotherapy or a targeted therapy).⁴³
• Genomic testing opens doors. If you have a BRCA2 mutation, PARP inhibitors become available. If your tumor is MSI-high, immunotherapy becomes an option. Without testing, these doors remain closed.
• Clinical trials can be considered at any point. Do not think of clinical trials as a "last resort." Some of the best outcomes come from trials that test new combinations early in the disease course.

Part 11: Clinical Trials at Recurrence — Why They Matter

Recurrence is one of the most important times to consider a clinical trial. Many of today's standard treatments — including enzalutamide for BCR (EMBARK), apalutamide for nmCRPC (SPARTAN), and Lutetium-177 PSMA for mCRPC (VISION) — were once only available through clinical trials.

Why consider a trial at recurrence?

• You may gain access to treatments not yet available to the general public.
• Trials often provide more frequent monitoring and closer follow-up than standard care.
• You contribute to knowledge that will help future patients.
• Many trials are designed specifically for the recurrence setting.

How to find trials:

• Ask your doctor — especially at academic medical centers.
• Visit ClinicalTrials.gov and search for "prostate cancer recurrence" or "biochemical recurrence."
• Contact the Prostate Cancer Foundation (PCF) or ZERO — The End of Prostate Cancer for trial-matching services.
• Some genomic testing companies (like Foundation Medicine) include trial-matching based on your tumor's mutations.

Common types of trials at recurrence:

• New combinations of hormone therapy and radiation in the salvage setting
• Novel imaging agents to better detect recurrence
• Targeted therapies based on specific mutations
• Immunotherapy combinations
• Radiopharmaceutical therapies (new PSMA-targeted agents)
• Artificial intelligence tools for treatment decision-making

Part 12: The Emotional "Second Hit" — Coping with Recurrence

Hearing that your cancer may be back is psychologically different from the initial diagnosis. Many men describe it as harder the second time.

Why recurrence feels different:

• Loss of the "cured" identity. After initial treatment, many men begin to think of themselves as cancer-free. A rising PSA shatters that sense of security.
• Treatment fatigue. You have already been through one round of treatment. The thought of going through it again can feel overwhelming.
• Fear of the unknown. "If the first treatment did not work, will anything work?" This is a common but usually unfounded fear.
• Impact on relationships. Partners and family members who thought the cancer chapter was closed now face renewed anxiety.

Coping strategies:

• Knowledge is power. Understanding that most biochemical recurrences are slow-growing and treatable can significantly reduce anxiety. Re-read Parts 1 and 9 of this chapter.
• Stay connected. Support groups — both in-person and online — are invaluable. Hearing from other men who have been through recurrence and are doing well provides perspective that no medical textbook can.
• Professional support. A psychologist or counselor experienced in cancer care can help you process the emotions of recurrence. Many cancer centers have dedicated psycho-oncology services.
• Mindfulness and stress reduction. Meditation, yoga, and breathing exercises have been shown to reduce anxiety and improve quality of life in cancer patients.⁴⁴
• Physical activity. Exercise is one of the most effective tools for managing the emotional and physical effects of cancer and its treatment. Even a daily 30-minute walk can make a meaningful difference.
• Communicate with your partner. Recurrence affects the whole family. Open, honest conversations — even when difficult — strengthen relationships and reduce isolation.

When to seek help immediately:

• Persistent feelings of hopelessness or despair
• Inability to sleep, eat, or function in daily life
• Thoughts of self-harm
• Withdrawal from family, friends, and activities you once enjoyed

These are signs that professional support is needed — and there is no shame in asking for it.

Part 13: When to Consider Palliative Care

The word "palliative" often frightens patients because they associate it with end-of-life care. But palliative care is not hospice. It is an additional layer of support focused on improving quality of life at any stage of disease.

What palliative care provides:

• Expert management of pain, fatigue, nausea, and other symptoms
• Help with side effects of treatment (hot flashes, bone pain, neuropathy)
• Emotional and psychological support
• Assistance with treatment decision-making
• Coordination of care between multiple specialists
• Support for family members and caregivers

When to consider palliative care:

• At any point when symptoms are affecting quality of life
• When managing multiple side effects from systemic therapy
• When facing difficult treatment decisions
• When transitioning from active treatment to supportive care
• At the metastatic CRPC stage — palliative care has been shown to improve both quality of life and, in some cancers, even survival when integrated early.⁴⁵

Palliative care does NOT mean giving up. You can receive palliative care alongside active cancer treatment. Think of it as adding another specialist to your team — one whose sole focus is making you feel as good as possible.

Part 14: The "My PSA Is Rising — What Now?" Decision Flowchart

This is a simplified guide to help you understand the steps your doctor will take when PSA rises after treatment. It is NOT a substitute for medical advice — every situation is unique.

Step 1: Confirm the PSA rise

• Repeat PSA in 4–8 weeks to confirm the trend.
• A single elevated PSA does not necessarily mean recurrence.

Step 2: Determine the clinical context

• Was your initial treatment surgery or radiation?
• How long has it been since treatment?
• How fast is PSA rising (PSA doubling time)?

Step 3: Get appropriate imaging

• PSMA PET-CT is the preferred imaging study for most patients with BCR.
• Additional imaging (MRI, bone scan, CT) may be ordered based on findings.

Step 4: Risk-stratify

• Low-risk BCR (slow PSADT, favorable pathology): Monitoring may be appropriate.
• High-risk BCR (fast PSADT, adverse features): Treatment is generally recommended.

Step 5: Treatment decision

• After surgery → Salvage radiation ± ADT (earlier is better)
• After radiation → Confirm local recurrence with biopsy → Local salvage therapy OR systemic therapy
• Distant metastases found → Systemic therapy (see Chapter 12)
• No metastases, high-risk BCR → Consider enzalutamide ± leuprolide (EMBARK)

Step 6: Follow-up

• Regular PSA monitoring after salvage treatment
• Imaging as indicated
• Quality of life assessment and support

Myth vs. Fact

Myth: "If my cancer comes back, it means my first treatment failed."

Fact: Recurrence is a known possibility with any cancer treatment. It does not mean the wrong choice was made. Even the best surgeons and radiation oncologists see recurrences because some cancer cells can be microscopic and undetectable at the time of initial treatment.

Myth: "Recurrence means I am going to die from prostate cancer."

Fact: Most men with biochemical recurrence will NOT die from prostate cancer. With modern treatments, 10-year prostate cancer-specific survival after BCR exceeds 95% for many patients.³ ⁴

Myth: "If I had radiation first, there is nothing left to do."

Fact: Multiple salvage options exist after radiation, including surgery, HIFU, cryotherapy, reirradiation, and systemic therapy. Outcomes are comparable across modalities.³⁷ ³⁸

Myth: "A rising PSA always means cancer is back."

Fact: After radiation, a PSA bounce (temporary rise) occurs in 25–30% of men and is NOT recurrence. Even after surgery, very low PSA levels can fluctuate without indicating true recurrence.

Myth: "Castration-resistant means untreatable."

Fact: Multiple effective therapies exist for CRPC, including novel hormone agents, chemotherapy, immunotherapy, PARP inhibitors, and radiopharmaceuticals. Men with mCRPC can live for years with good quality of life.⁴²

Myth: "Clinical trials are a last resort."

Fact: Clinical trials are available at every stage of recurrence and often provide access to the most advanced treatments. Many of today's standard therapies were yesterday's clinical trials.

Questions to Ask Your Doctor

If your PSA is rising after surgery:

1. What is my PSA doubling time, and what does it mean for my prognosis?
2. Should I get a PSMA PET scan? At what PSA level?
3. Am I a candidate for salvage radiation? When should we start?
4. Should hormone therapy be added to salvage radiation in my case?
5. Would a genomic test (like Decipher) on my surgical specimen help guide the decision?
6. What are the expected side effects of salvage radiation?

If your PSA is rising after radiation:

1. Could this be a PSA bounce rather than true recurrence?
2. Do I need a biopsy to confirm local recurrence?
3. What local salvage options are available to me?
4. Should I be treated at a specialized center for salvage therapy?
5. What are the risks and benefits of each salvage option compared to hormone therapy?
6. How will salvage treatment affect my urinary and sexual function?

If you have been diagnosed with CRPC:

1. Has my tumor been tested for HRR mutations (BRCA1/2, ATM)?
2. Has my tumor been tested for MSI-H/dMMR status?
3. Am I eligible for any targeted therapies based on my tumor's genetic profile?
4. What is the sequence of treatments you recommend, and why?
5. Are there clinical trials I should consider?
6. Should I see a palliative care specialist to help manage symptoms and side effects?

General questions at any recurrence:

1. How urgent is this? Do I have time to get a second opinion?
2. What is the goal of the next treatment — cure, long-term control, or symptom management?
3. How will this treatment affect my quality of life?
4. Are there support groups for men dealing with recurrent prostate cancer?
5. What can my family do to support me through this?

Key Takeaways

1. A rising PSA after treatment is common and usually manageable. Biochemical recurrence occurs in 20–40% of men, but most will not die from prostate cancer.
2. PSA doubling time is the most important number. A slow doubling time (>12 months) suggests slow-growing disease that may only need monitoring. A fast doubling time (9 months) warrants treatment.
3. After surgery, salvage radiation works best when given early — ideally when PSA is still below 0.5 ng/mL. Do not wait.
4. After radiation, multiple salvage options exist — including HIFU, cryotherapy, reirradiation, and surgery. Outcomes are comparable, but side effect profiles differ. Seek an experienced center.
5. Even castration-resistant prostate cancer has multiple effective treatments. Genomic testing can identify targeted therapies. Clinical trials offer access to cutting-edge options. Palliative care improves quality of life at any stage.

Support Resources

• Prostate Cancer Foundation (PCF): pcf.org — comprehensive information on recurrence and clinical trial matching
• ZERO — The End of Prostate Cancer: zerocancer.org — support groups, educational resources, and a helpline
• Us TOO International: ustoo.org — peer support groups specifically for men with prostate cancer, including recurrence-specific groups
• Cancer Support Community: cancersupportcommunity.org — free counseling, support groups, and educational workshops
• Man to Man (American Cancer Society): cancer.org — one-on-one support from trained prostate cancer survivors
• NCCN Patient Guidelines: nccn.org/patients — free, patient-friendly versions of the treatment guidelines
• ClinicalTrials.gov: clinicaltrials.gov — searchable database of all registered clinical trials
• National Cancer Institute Cancer Information Service: 1-800-4-CANCER — trained specialists who can answer questions and help find trials

References for Chapter 13

References

1. Pound CR, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-1597.
2. Zumsteg ZS, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients treated with definitive external beam radiotherapy. Eur Urol. 2015;67(6):1009-1016.
3. Spratt DE, et al. Prostate cancer: AUA/ASTRO/SUO guideline, part I: early detection and diagnosis. J Urol. 2024;212(1):11-25.
4. Spratt DE, et al. Prostate cancer: AUA/ASTRO/SUO guideline, part II: management. J Urol. 2024;212(1):26-37.
5. Freedland SJ, et al. Time to prostate-specific antigen recurrence after radical prostatectomy and risk of prostate cancer-specific mortality. Urology. 2006;68(6):1231-1236.
6. Amling CL, et al. Defining prostate-specific antigen progression after radical prostatectomy. J Urol. 2001;166(4):1322-1327.
7. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Monitoring (PROS-9).
8. Lowrance WT, et al. AUA/ASTRO/SUO guideline on advanced prostate cancer. J Urol. 2021;205(1):14-21.
9. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Radical Prostatectomy PSA Persistence/Recurrence (PROS-10).
10. Spratt DE, et al. Individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy. J Clin Oncol. 2017;35(18):1991-1998.
11. Freedland SJ, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433-439.
12. Parker CC, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396(10260):1413-1421.
13. Kneebone A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21(10):1331-1340.
14. Sargos P, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341-1352.
15. Vale CL, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data (ARTISTIC). Lancet. 2020;396(10260):1422-1431.
16. Parker CC, et al. RADICALS-RT 10-year outcomes: timing of radiotherapy after radical prostatectomy. Lancet. 2024;404(10467):2015-2025.
17. Stephenson AJ, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035-2041.
18. Tendulkar RD, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648-3654.
19. Carrie C, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740-1749.
20. Shipley WU, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417-428.
21. Pollack A, et al. Short-term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT trial. J Clin Oncol. 2022;40(31):3611-3621.
22. Dess RT, et al. Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol. 2020;6(5):735-743.
23. Murthy V, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39(11):1234-1242.
24. Fendler WP, et al. 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments. J Nucl Med. 2017;58(10):1642-1649.
25. Perera M, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926-937.
26. Calais J, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286-1294.
27. Defined by systematic review and meta-analysis of 43 studies (8,119 patients) on PSMA PET detection rates in biochemical recurrence. Eur Urol. 2025.
28. Fendler WP, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856-863.
29. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Treatment and Monitoring for Second Biochemical Recurrence (PROS-12).
30. Freedland SJ, et al. Enzalutamide and leuprolide with or without enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer after local therapy (EMBARK): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;402(10414):1671-1681.
31. Freedland SJ, et al. EMBARK: enzalutamide in high-risk biochemical recurrence — final overall survival analysis. ASCO GU. 2025.
32. Freedland SJ, et al. EMBARK: enzalutamide monotherapy vs. leuprolide — sexual function outcomes. Eur Urol. 2024.
33. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Discussion — EMBARK and high-risk BCR.
34. Roach M 3rd, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974.
35. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Radiation Therapy Recurrence (PROS-11).
36. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Principles of Local Secondary Therapy Post-Radiation (PROS-K).
37. Defined by the MASTER meta-analysis of 150 studies comparing salvage modalities after radiation failure. Eur Urol. 2025.
38. Matched cohort study of 923 patients comparing salvage focal therapy vs. salvage RP. Eur Urol. 2026.
39. Systematic review and meta-analysis of ADT-free survival after local salvage therapies. Eur Urol. 2026.
40. Marra G, et al. Focal therapy for radiorecurrent prostate cancer. Nat Rev Urol. 2024.
41. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Principles of Local Secondary Therapy Post-Radiation — Reirradiation (PROS-K).
42. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Workup and Treatment of M0 CRPC (PROS-14) and M1 CRPC (PROS-15).
43. de Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer (CARD). N Engl J Med. 2019;381(26):2506-2518.
44. Carlson LE, et al. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol in patients with breast cancer. Psychooncology. 2004;13(8):571-581.
45. Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.